NCT01865162View on ClinicalTrials.gov

Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Glioblastoma Multiforme
Interventions
OTHER

ketogenic diet

Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.

Trial Locations (1)

20817

MidAtlantic Epilepsy and Sleep Center, Bethesda

All Listed Sponsors
collaborator

University of Pittsburgh Medical Center

OTHER

lead

Mid-Atlantic Epilepsy and Sleep Center, LLC

OTHER

NCT01865162 - Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study | Biotech Hunter | Biotech Hunter